Takahashi M, Kushida K, Ishihara C, Denda M, Inoue T
Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Scand J Urol Nephrol. 1995 Jun;29(2):131-4. doi: 10.3109/00365599509180552.
Pentosidine, a fluorescent cross-link, is one of the advanced glycosylation end-products. It accumulates in human tissues, plasma and urine in diabetic and uremic patients. Using SP-Sephadex C-25 in the pretreatment for reversed-phase HPLC, we determined pentosidine levels in plasma before and after hemodialysis using cuprophane membranes from 18 patients (9 diabetic, 9 nondiabetic) with end-stage renal disease, as well as examined the hemodialysis efficiency of plasma pentosidine. We also measured beta 2-microglobulin levels in plasma before and after hemodialysis. The values of plasma pentosidine did not significantly change after hemodialysis. Also, plasma beta 2-microglobulin was not removed by hemodialysis. Hemodialysis efficiency of plasma pentosidine and beta 2-microglobulin was nil. In addition, there was a significant correlation between plasma levels of pentosidine and beta 2-microglobulin before hemodialysis in 116 uremic patients. The results indicated that hemodialysis could not eliminate pentosidine from plasma; therefore, pentosidine retention by the diseased kidney might be a major cause of elevated levels of pentosidine with uremia.
戊糖苷是一种荧光交联物，是晚期糖基化终产物之一。它在糖尿病和尿毒症患者的人体组织、血浆及尿液中蓄积。我们采用SP - 葡聚糖凝胶C - 25对反相高效液相色谱进行预处理，测定了18例终末期肾病患者（9例糖尿病患者，9例非糖尿病患者）使用铜仿膜进行血液透析前后血浆中的戊糖苷水平，并检测了血浆戊糖苷的血液透析效率。我们还测定了血液透析前后血浆中β2 - 微球蛋白的水平。血液透析后血浆戊糖苷的值无显著变化。此外，血液透析不能清除血浆中的β2 - 微球蛋白。血浆戊糖苷和β2 - 微球蛋白的血液透析效率为零。另外，在116例尿毒症患者中，血液透析前血浆戊糖苷水平与β2 - 微球蛋白水平之间存在显著相关性。结果表明，血液透析不能从血浆中清除戊糖苷；因此，患病肾脏对戊糖苷的潴留可能是尿毒症患者戊糖苷水平升高的主要原因。
